AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Study 12949595 — intervention group
Group type: COMPARATOR
Intervention: Control group (no intervention specified)
Number of subjects: 50
Study 10699133 — intervention group
Group type: EXPERIMENTAL
Intervention: PCR assay for Bordetella pertussis
Number of subjects: 392
Study 10699133 — intervention group
Group type: EXPERIMENTAL
Intervention: 3+ positive PCR results
Number of subjects: 392
Study 10699133 — intervention group
Group type: EXPERIMENTAL
Intervention: 2+ positive PCR results
Number of subjects: 392
Study 10699133 — intervention group
Group type: EXPERIMENTAL
Intervention: 1+ positive PCR results
Number of subjects: 392
Study 10699133 — intervention group
Group type: COMPARATOR
Intervention: Conventional culture
Number of subjects: 392
Study 8792943 — intervention group
Group type: EXPERIMENTAL
Intervention: Prescription medications (self-reported use)
Number of subjects: 1360
Study 8792943 — intervention group
Group type: COMPARATOR
Intervention: Gender comparison in medication use
Number of subjects: 1360
Study 8792943 — intervention group
Group type: EXPERIMENTAL
Intervention: Factors associated with greater medication use
Number of subjects: 1360
Study 8792943 — intervention group
Group type: EXPERIMENTAL
Intervention: Age-related medication use
Number of subjects: 1360
Study 8792943 — intervention group
Group type: EXPERIMENTAL
Intervention: Gender-related medication use
Number of subjects: 1360
Study 1634705 — intervention group
Group type: EXPERIMENTAL
Intervention: Milacemide 1200 mg/day for 1 month
Number of subjects: 228
Study 1634705 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 228
Study 6378805 — intervention group
Group type: EXPERIMENTAL
Intervention: Metoprolol (beta 1-selective blocker)
Number of subjects: 585
Study 6378805 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 585
Study 3949566 — intervention group
Group type: EXPERIMENTAL
Intervention: Chemotherapy only
Number of subjects: 202
Study 3949566 — intervention group
Group type: EXPERIMENTAL
Intervention: Radiotherapy only
Number of subjects: 202
Study 3949566 — intervention group
Group type: EXPERIMENTAL
Intervention: Combined radiotherapy and chemotherapy
Number of subjects: 202
Study 3949566 — intervention group
Group type: COMPARATOR
Intervention: No further therapy
Number of subjects: 202
Study 3949566 — intervention group
Group type: EXPERIMENTAL
Intervention: Perineal irradiation
Number of subjects: 202
Study 3949566 — intervention group
Group type: EXPERIMENTAL
Intervention: Patients with tumors within 2 cm of the anorectal junction
Number of subjects: 202
Study 3949566 — intervention group
Group type: COMPARATOR
Intervention: Patients with tumors more than 2 cm from the anus
Number of subjects: 202
Study 31953532 — intervention group
Group type: EXPERIMENTAL
Intervention: BeEAM regimen
Number of subjects: 168
Study 31953532 — intervention group
Group type: COMPARATOR
Intervention: BEAM regimen
Number of subjects: 168
Study 29441742 — intervention group
Group type: EXPERIMENTAL
Intervention: Mycophenolate mofetil (MMF) combined with low-dose corticosteroids
Number of subjects: 39
Study 29441742 — intervention group
Group type: COMPARATOR
Intervention: Cyclosporine (CsA) combined with low-dose corticosteroids
Number of subjects: 39
Study 29441742 — intervention group
Group type: EXPERIMENTAL
Intervention: Both groups
Number of subjects: 39
Study 27039125 — intervention group
Group type: EXPERIMENTAL
Intervention: Albiglutide 30 mg
Number of subjects: 82
Study 27039125 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 82
Study 25765590 — intervention group
Group type: EXPERIMENTAL
Intervention: Enoxaparin 1 mg/kg (maximum 100 mg) subcutaneously every 12 hours for 30 days
Number of subjects: 60
Study 25765590 — intervention group
Group type: COMPARATOR
Intervention: Traditional anticoagulation (intravenous heparin followed by oral warfarin for 3 months)
Number of subjects: 60
Study 23534831 — intervention group
Group type: EXPERIMENTAL
Intervention: Video feedback intervention during the Family Check-Up (FCU) protocol
Number of subjects: 79
Study 23534831 — intervention group
Group type: COMPARATOR
Intervention: Family Check-Up (FCU) intervention
Number of subjects: 79
Study 21183917 — intervention group
Group type: EXPERIMENTAL
Intervention: Omaron (25 mg of cinnarizine and 400 mg of piracetam), 1 tablet 3 times a day for 12 weeks
Number of subjects: 33
Study 21183917 — intervention group
Group type: COMPARATOR
Intervention: Control group (no nootropics)
Number of subjects: 33
Study 18849119 — intervention group
Group type: EXPERIMENTAL
Intervention: FDG-PET
Number of subjects: 0
Study 18849119 — intervention group
Group type: EXPERIMENTAL
Intervention: Hybrid PET/CT
Number of subjects: 0
Study 16688202 — intervention group
Group type: EXPERIMENTAL
Intervention: High-flow nasal cannula (HFNC) at 3, 4, and 5 l/min
Number of subjects: 18
Study 16688202 — intervention group
Group type: COMPARATOR
Intervention: Nasal continuous positive airway pressure (NCPAP) at 6 cm H2O
Number of subjects: 18
Study 12568837 — intervention group
Group type: EXPERIMENTAL
Intervention: L‐carnitine therapy 2 g/day
Number of subjects: 100
Study 12568837 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 100
Study 10982201 — intervention group
Group type: EXPERIMENTAL
Intervention: Sertraline treatment
Number of subjects: 62
Study 9816321 — intervention group
Group type: EXPERIMENTAL
Intervention: UFT at a dose of 400 mg/m2/day administered as three divided doses (every 8 h)
Number of subjects: 0
Study 9816321 — intervention group
Group type: COMPARATOR
Intervention: Single daily dosing of UFT
Number of subjects: 0
Study 9816321 — intervention group
Group type: EXPERIMENTAL
Intervention: UFT at a dose of 300 mg/m2/day
Number of subjects: 0
Study 9816321 — intervention group
Group type: EXPERIMENTAL
Intervention: UFT at a dose of 400 mg/m2/day
Number of subjects: 0
Study 1466210 — intervention group
Group type: EXPERIMENTAL
Intervention: Brotizolam 0.25-0.50 mg sublingually
Number of subjects: 62
Study 1466210 — intervention group
Group type: COMPARATOR
Intervention: Diazepam 5-10 mg orally
Number of subjects: 62
Study 6717216 — intervention group
Group type: EXPERIMENTAL
Intervention: Moxalactam (30 mg/kg) for 3 doses postoperatively
Number of subjects: 30
Study 6717216 — intervention group
Group type: COMPARATOR
Intervention: Moxalactam (30 mg/kg) for 6 doses postoperatively
Number of subjects: 30
Study 30341029 — intervention group
Group type: EXPERIMENTAL
Intervention: Diabetic patients receiving metformin
Number of subjects: 1600
Study 30341029 — intervention group
Group type: EXPERIMENTAL
Intervention: Diabetic patients not receiving metformin
Number of subjects: 1600
Study 30341029 — intervention group
Group type: EXPERIMENTAL
Intervention: Nondiabetic patients
Number of subjects: 1600
Study 30341029 — intervention group
Group type: COMPARATOR
Intervention: Overall survival factors
Number of subjects: 1600
Study 28667826 — intervention group
Group type: EXPERIMENTAL
Intervention: Intensive counselling by a practice nurse (PN)
Number of subjects: 295
Study 28667826 — intervention group
Group type: COMPARATOR
Intervention: Brief advice by a general practitioner (GP)
Number of subjects: 295
Study 25825138 — intervention group
Group type: EXPERIMENTAL
Intervention: Compressive cryotherapy (CC)
Number of subjects: 46
Study 25825138 — intervention group
Group type: COMPARATOR
Intervention: Standard ice wrap (IW)
Number of subjects: 46
Study 23370528 — intervention group
Group type: EXPERIMENTAL
Intervention: L-Name (20 μg min⁻¹ kg⁻¹) during OGTT
Number of subjects: 29
Study 23370528 — intervention group
Group type: EXPERIMENTAL
Intervention: L-Name (at rates of 2.5, 5, 10 and 20 μg min⁻¹ kg⁻¹) during hyperglycaemic clamps
Number of subjects: 29
Study 23370528 — intervention group
Group type: COMPARATOR
Intervention: Saline during OGTT
Number of subjects: 29
Study 23370528 — intervention group
Group type: COMPARATOR
Intervention: Saline during hyperglycaemic clamps
Number of subjects: 29
Study 22214253 — intervention group
Group type: EXPERIMENTAL
Intervention: Eucommia extract 500 mg three times daily for eight weeks
Number of subjects: 54
Study 22214253 — intervention group
Group type: COMPARATOR
Intervention: Eucommia extract 0.5% w/v
Number of subjects: 54
Study 22214253 — intervention group
Group type: EXPERIMENTAL
Intervention: Eucommia extract 1 g three times daily for two weeks
Number of subjects: 54
Study 19597364 — intervention group
Group type: EXPERIMENTAL
Intervention: Psychodynamic Group Therapy (PGT) plus clonazepam
Number of subjects: 57
Study 19597364 — intervention group
Group type: COMPARATOR
Intervention: Clonazepam
Number of subjects: 57
Study 16899833 — intervention group
Group type: EXPERIMENTAL
Intervention: Chronic cough patients (all groups)
Number of subjects: 24
Study 16899833 — intervention group
Group type: EXPERIMENTAL
Intervention: Chronic cough patients (group 1: intrapulmonary diseases)
Number of subjects: 24
Study 16899833 — intervention group
Group type: EXPERIMENTAL
Intervention: Chronic cough patients (group 2: extrapulmonary diseases)
Number of subjects: 24
Study 16899833 — intervention group
Group type: EXPERIMENTAL
Intervention: Chronic cough patients (group 3: unexplained cough)
Number of subjects: 24
Study 16899833 — intervention group
Group type: COMPARATOR
Intervention: Control subjects (nonsmoking, asymptomatic)
Number of subjects: 24
Study 14746420 — intervention group
Group type: EXPERIMENTAL
Intervention: Butorphanol
Number of subjects: 94
Study 14746420 — intervention group
Group type: COMPARATOR
Intervention: Morphine sulfate
Number of subjects: 94
Study 11669470 — intervention group
Group type: EXPERIMENTAL
Intervention: Remifentanil (target plasma concentrations: 0, 1.2, 1.8, 2.4, 3, 3.6, 4.8, and 6 ng/ml)
Number of subjects: 16
Study 11669470 — intervention group
Group type: EXPERIMENTAL
Intervention: Remifentanil (target plasma concentrations)
Number of subjects: 16
Study 9721772 — intervention group
Group type: EXPERIMENTAL
Intervention: 0.625 mg of conjugated equine estrogen (n = 20)
Number of subjects: 55
Study 9721772 — intervention group
Group type: EXPERIMENTAL
Intervention: 5 mg of simvastatin (n = 18)
Number of subjects: 55
Study 9721772 — intervention group
Group type: EXPERIMENTAL
Intervention: Combination therapy (n = 17)
Number of subjects: 55
Study 9721772 — intervention group
Group type: COMPARATOR
Intervention: Estrogen treatment
Number of subjects: 55
Study 8032829 — intervention group
Group type: EXPERIMENTAL
Intervention: One instillation of thiotepa at the time of resection
Number of subjects: 417
Study 8032829 — intervention group
Group type: EXPERIMENTAL
Intervention: Five instillations of thiotepa (one at time of resection and then at 3-month intervals for one year)
Number of subjects: 417
Study 8032829 — intervention group
Group type: COMPARATOR
Intervention: No thiotepa (control group)
Number of subjects: 417
Study 2512938 — intervention group
Group type: EXPERIMENTAL
Intervention: enprostil (35 micrograms)
Number of subjects: 6
Study 2512938 — intervention group
Group type: COMPARATOR
Intervention: placebo
Number of subjects: 6
Study 958162 — intervention group
Group type: EXPERIMENTAL
Intervention: Porfiromycin (75 mg/M2 every 6-8 weeks as a single bolus i.v. injection)
Number of subjects: 63
Study 958162 — intervention group
Group type: COMPARATOR
Intervention: Mitomycin-C (22.5 mg/M2 every 6-8 weeks as a single bolus i.v. injection)
Number of subjects: 63
Study 958162 — intervention group
Group type: COMPARATOR
Intervention: Mitomycin-C
Number of subjects: 63
Study 958162 — intervention group
Group type: EXPERIMENTAL
Intervention: Porfiromycin
Number of subjects: 63
Study 958162 — intervention group
Group type: EXPERIMENTAL
Intervention: Both drugs
Number of subjects: 63
Study 31008902 — intervention group
Group type: EXPERIMENTAL
Intervention: High-quality foster care
Number of subjects: 127
Study 31008902 — intervention group
Group type: COMPARATOR
Intervention: Care as usual (institutional care)
Number of subjects: 127
Study 31008902 — intervention group
Group type: EXPERIMENTAL
Intervention: Age of placement into foster care
Number of subjects: 127
Study 28928303 — intervention group
Group type: EXPERIMENTAL
Intervention: Vitamin D status measurement (25‐hydroxyvitamin D)
Number of subjects: 400
Study 28928303 — intervention group
Group type: EXPERIMENTAL
Intervention: Sociobehavioral risk factors analysis
Number of subjects: 400
Study 26185429 — intervention group
Group type: EXPERIMENTAL
Intervention: teriparatide 20 μg/day
Number of subjects: 207
Study 26185429 — intervention group
Group type: COMPARATOR
Intervention: placebo
Number of subjects: 207
Study 23647283 — intervention group
Group type: COMPARATOR
Intervention: Self-help treatment administered in a group
Number of subjects: 1073
Study 23647283 — intervention group
Group type: EXPERIMENTAL
Intervention: Longer treatment duration
Number of subjects: 1073
Study 23647283 — intervention group
Group type: EXPERIMENTAL
Intervention: African American participants
Number of subjects: 1073
Study 23647283 — intervention group
Group type: EXPERIMENTAL
Intervention: Lower level of education
Number of subjects: 1073
Study 21722033 — intervention group
Group type: EXPERIMENTAL
Intervention: Culturally enriched FRIENDS for Life program
Number of subjects: 533
Study 21722033 — intervention group
Group type: COMPARATOR
Intervention: Control group (not specified)
Number of subjects: 533
Study 19644647 — intervention group
Group type: EXPERIMENTAL
Intervention: 0.25% bupivacaine pre‐peritoneally after placing mesh
Number of subjects: 53
Study 19644647 — intervention group
Group type: COMPARATOR
Intervention: Saline pre‐peritoneally after placing mesh
Number of subjects: 53
Study 17127811 — intervention group
Group type: EXPERIMENTAL
Intervention: Pitavastatin
Number of subjects: 0
Study 17127811 — intervention group
Group type: COMPARATOR
Intervention: Atorvastatin
Number of subjects: 0
Study 15383190 — intervention group
Group type: EXPERIMENTAL
Intervention: Transdermal fentanyl (TDF)
Number of subjects: 1220
Study 15383190 — intervention group
Group type: COMPARATOR
Intervention: Sustained-release oral morphine (SRM)
Number of subjects: 1220
Study 11744907 — intervention group
Group type: EXPERIMENTAL
Intervention: Vasopressin
Number of subjects: 117
Study 11744907 — intervention group
Group type: COMPARATOR
Intervention: Normal saline solution
Number of subjects: 117
Study 9247842 — intervention group
Group type: EXPERIMENTAL
Intervention: Oral tolterodine 3.2 mg
Number of subjects: 17
Study 9247842 — intervention group
Group type: EXPERIMENTAL
Intervention: Oral tolterodine 6.4 mg
Number of subjects: 17
Study 9247842 — intervention group
Group type: EXPERIMENTAL
Intervention: Oral tolterodine 12.8 mg
Number of subjects: 17
Study 9247842 — intervention group
Group type: EXPERIMENTAL
Intervention: Oral tolterodine (14C) 5 mg
Number of subjects: 17
Study 7682488 — intervention group
Group type: EXPERIMENTAL
Intervention: L-carnitine (6 g daily)
Number of subjects: 30
Study 7682488 — intervention group
Group type: COMPARATOR
Intervention: Propafenone (900 mg daily)
Number of subjects: 30
Study 7682488 — intervention group
Group type: EXPERIMENTAL
Intervention: Propafenone (900 mg daily) plus L-carnitine (6 g daily)
Number of subjects: 30
Study 3117401 — intervention group
Group type: EXPERIMENTAL
Intervention: Intravesical instillation of 20‐30 mg adriamycin for 4 weeks or 2 years
Number of subjects: 259
Study 3117401 — intervention group
Group type: EXPERIMENTAL
Intervention: Intravesical instillation of 20 mg mitomycin C for 4 weeks or 2 years
Number of subjects: 259
Study 3117401 — intervention group
Group type: COMPARATOR
Intervention: Control group (no instillation)
Number of subjects: 259
Study 31870492 — intervention group
Group type: EXPERIMENTAL
Intervention: Intracoronary tenecteplase (TNK) 4 mg
Number of subjects: 40
Study 31870492 — intervention group
Group type: COMPARATOR
Intervention: Intracoronary saline placebo
Number of subjects: 40
Study 29480503 — intervention group
Group type: EXPERIMENTAL
Intervention: Child Life and Attention Skills (CLAS) program
Number of subjects: 0
Study 29480503 — intervention group
Group type: EXPERIMENTAL
Intervention: Parent-focused treatment (PFT)
Number of subjects: 0
Study 29480503 — intervention group
Group type: COMPARATOR
Intervention: Community-based treatment as usual (TAU)
Number of subjects: 0
Study 26086285 — intervention group
Group type: EXPERIMENTAL
Intervention: Alizapride 100 mg
Number of subjects: 523
Study 26086285 — intervention group
Group type: EXPERIMENTAL
Intervention: Ondansetron 4 mg
Number of subjects: 523
Study 26086285 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 523
Study 25330088 — intervention group
Group type: EXPERIMENTAL
Intervention: Pioglitazone 45 mg
Number of subjects: 12
Study 25330088 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 12
Study 23556437 — intervention group
Group type: EXPERIMENTAL
Intervention: Vitamin D₃ (400 IU/d)
Number of subjects: 39
Study 23556437 — intervention group
Group type: EXPERIMENTAL
Intervention: Vitamin D₂ (400 IU/d)
Number of subjects: 39
Study 19787711 — intervention group
Group type: EXPERIMENTAL
Intervention: Non-surgical therapy (continence pessary, pelvic floor muscle training or combined)
Number of subjects: 444
Study 19787711 — intervention group
Group type: EXPERIMENTAL
Intervention: QUID Stress scores
Number of subjects: 444
Study 19787711 — intervention group
Group type: EXPERIMENTAL
Intervention: QUID Urge scores
Number of subjects: 444
Study 19787711 — intervention group
Group type: EXPERIMENTAL
Intervention: QUID Total, Stress, and Urge scores
Number of subjects: 444
Study 18382004 — intervention group
Group type: EXPERIMENTAL
Intervention: Comprehensive psychosocial services
Number of subjects: 541
Study 18382004 — intervention group
Group type: COMPARATOR
Intervention: Usual community care
Number of subjects: 541
Study 16735085 — intervention group
Group type: EXPERIMENTAL
Intervention: 116E (10^5 FFu)
Number of subjects: 90
Study 16735085 — intervention group
Group type: EXPERIMENTAL
Intervention: I321 (10^5 FFu)
Number of subjects: 90
Study 16735085 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 90
Study 14581122 — intervention group
Group type: EXPERIMENTAL
Intervention: Lidocaine patch 5%
Number of subjects: 40
Study 14581122 — intervention group
Group type: COMPARATOR
Intervention: Topically applied capsaicin
Number of subjects: 40
Study 14581122 — intervention group
Group type: COMPARATOR
Intervention: Systemic treatment with gabapentin
Number of subjects: 40
Study 10809260 — intervention group
Group type: COMPARATOR
Intervention: Dopamine (4-hr infusions at doses of placebo, 3, 7, and 12 microg/kg/min)
Number of subjects: 12
Study 10809260 — intervention group
Group type: EXPERIMENTAL
Intervention: Dobutamine (4-hr infusions at doses of placebo, 3, 7, and 12 microg/kg/min)
Number of subjects: 12
Study 8613041 — intervention group
Group type: EXPERIMENTAL
Intervention: Loxiglumide (10 mg.kg‐1.h‐1)
Number of subjects: 12
Study 8613041 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 12
Study 8613041 — intervention group
Group type: EXPERIMENTAL
Intervention: Duodenal lipid (20% Intralipid)
Number of subjects: 12
Study 8613041 — intervention group
Group type: COMPARATOR
Intervention: Duodenal saline (0.9% saline)
Number of subjects: 12
Study 9071422 — intervention group
Group type: EXPERIMENTAL
Intervention: Azithromycin 2.0 g orally
Number of subjects: 724
Study 9071422 — intervention group
Group type: COMPARATOR
Intervention: Ceftriaxone 250 mg intramuscularly
Number of subjects: 724
Study 3340314 — intervention group
Group type: EXPERIMENTAL
Intervention: Ionic contrast media
Number of subjects: 0
Study 3340314 — intervention group
Group type: EXPERIMENTAL
Intervention: Non-ionic contrast media
Number of subjects: 0
Study 3340314 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 0
Study 29730251 — intervention group
Group type: EXPERIMENTAL
Intervention: left prefrontal iTBS
Number of subjects: 56
Study 29730251 — intervention group
Group type: EXPERIMENTAL
Intervention: combined right prefrontal cTBS and left prefrontal iTBS
Number of subjects: 56
Study 29730251 — intervention group
Group type: EXPERIMENTAL
Intervention: right prefrontal cTBS
Number of subjects: 56
Study 29730251 — intervention group
Group type: COMPARATOR
Intervention: sham‐TBS
Number of subjects: 56
Study 28034709 — intervention group
Group type: EXPERIMENTAL
Intervention: Dual wire-maintaining technique (DWMT)
Number of subjects: 241
Study 28034709 — intervention group
Group type: COMPARATOR
Intervention: Conventional technique (CT)
Number of subjects: 241
Study 25600977 — intervention group
Group type: EXPERIMENTAL
Intervention: Low C-form (10 mg lenvatinib, <4% crystalline)
Number of subjects: 59
Study 25600977 — intervention group
Group type: EXPERIMENTAL
Intervention: High C-form (10 mg lenvatinib, 38% crystalline)
Number of subjects: 59
Study 25600977 — intervention group
Group type: COMPARATOR
Intervention: Reference C-form (10 mg lenvatinib, 15% crystalline)
Number of subjects: 59
Study 23349433 — intervention group
Group type: EXPERIMENTAL
Intervention: Shortened subseries with W = 7 tests
Number of subjects: 0
Study 23349433 — intervention group
Group type: COMPARATOR
Intervention: Entire sequence of visual fields
Number of subjects: 0
Study 23349433 — intervention group
Group type: EXPERIMENTAL
Intervention: Window lengths 6 ≤ W ≤ 9
Number of subjects: 0
Study 20842170 — intervention group
Group type: EXPERIMENTAL
Intervention: Long-chain pullulan (indigestible)
Number of subjects: 35
Study 20842170 — intervention group
Group type: EXPERIMENTAL
Intervention: Medium-chain pullulan (slowly but completely digestible)
Number of subjects: 35
Study 20842170 — intervention group
Group type: COMPARATOR
Intervention: Maltodextrin (rapidly digestible)
Number of subjects: 35
Study 17433718 — intervention group
Group type: EXPERIMENTAL
Intervention: Participants with autism
Number of subjects: 0
Study 17433718 — intervention group
Group type: COMPARATOR
Intervention: Control group (without autism)
Number of subjects: 0
Study 16418630 — intervention group
Group type: EXPERIMENTAL
Intervention: Left‐sided blindness by enucleation (group 2)
Number of subjects: 60
Study 16418630 — intervention group
Group type: EXPERIMENTAL
Intervention: Right‐sided blindness (group 3)
Number of subjects: 60
Study 16418630 — intervention group
Group type: COMPARATOR
Intervention: No visual impairment (group 1)
Number of subjects: 60
Study 16418630 — intervention group
Group type: EXPERIMENTAL
Intervention: All groups
Number of subjects: 60
Study 14507756 — intervention group
Group type: EXPERIMENTAL
Intervention: 2% econazole
Number of subjects: 116
Study 14507756 — intervention group
Group type: COMPARATOR
Intervention: 5% natamycin
Number of subjects: 116
Study 10874974 — intervention group
Group type: EXPERIMENTAL
Intervention: Intraarterial chemoperfusion (CP) with mitoxantrone (820 mg/m2 for 1-2 hours)
Number of subjects: 30
Study 10874974 — intervention group
Group type: COMPARATOR
Intervention: Intraarterial embolization therapy (ET) using Histoacryl or Ethibloc
Number of subjects: 30
Study 7594333 — intervention group
Group type: EXPERIMENTAL
Intervention: 15 mg lansoprazole by slow intravenous injection twice daily for 3 days (six injections)
Number of subjects: 82
Study 7594333 — intervention group
Group type: EXPERIMENTAL
Intervention: 30 mg lansoprazole by slow intravenous injection twice daily for 3 days (six injections)
Number of subjects: 82
Study 2102066 — intervention group
Group type: EXPERIMENTAL
Intervention: kanamycin sulphate alternated to polydeoxyribonucleotide vaginal suppositories
Number of subjects: 240